此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Grape Seed Powder and Vitamin C Supplementation for Liver Disease (Acquired Hepatic Jaundice) (AHJ)

2026年5月7日 更新者:Aleena Zahid、University of Lahore Hospital (ULH)

Impact of Grape (VITIS VINIFERA) Seed Powder Along With Vitamin C Supplementation on Serum Bilirubin Levels in Patients With Acquired Hepatic Jaundice

Jaundice is a frequent medical problem that affects people of all ages. It is important to note that jaundice is not an actual sickness as such itself but rather a symptom of liver illness brought on by an increase in the quantity of bilirubin circulating in the blood owing to improper metabolism and excretion in the urine. The aim of this investigation is to investigate the impact of grape (Vitis Vinifera) seed powder along with vitamin C supplementation on serum bilirubin levels in patients with acquired hepatic jaundice. In addition, it's the first research of its kind to investigate the aforementioned function of grape seed extract with vitamin C in healthy individuals specifically.

研究概览

地位

完全的

条件

详细说明

According to my study, the division of patients was done between two groups: one was named as Conventional group (CG) and other was named as Intervention group (IG). The conventional treatment group received only conventional medication and intervention group was given Grape-C capsule with dose of one tablet per day for 4 weeks after lunch along with conventional medication. Grape-C capsule continued for 4 weeks and the data was obtained at the initiation and at end of intervention (after 4th week).

According to my research study results the intervention group had a significant decrease in bilirubin levels, ALT, AST, ALP and increase the albumin and gamma glutamyl transferase (GGT) compared to the conventional group. The p-values for the comparison between pre and post intervention levels were highly significant rather than the conventional groups indicating a statistically significant difference.

研究类型

介入性

注册 (实际的)

24

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Punjab Province
      • Lahore、Punjab Province、巴基斯坦
        • University of Lahore

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • Both men and women
  • Participants between the ages of 20-40 years will be included
  • Patients having signs and symptoms of acquired hepatic jaundice
  • Patients having high serum bilirubin, albumin, ALT, AST, ALP levels
  • The patient having ALT level more than 10-50 U/L were included
  • The participants having AST level above than 0-40 IU/L were included in this study
  • Patients having ALP level more than 30 - 130 U/L were included in this research study
  • Patients having level of bilirubin above than 0 - 21 μmol/L were included in this investigation
  • Participants having the range of albumin more than 30-50 g/L were included in this research
  • Participants those were underweighted were included

Exclusion Criteria:

  • Patients who already taking any supplement or medication
  • Participants taking any anti-inflammatory medications
  • People who were suffering from any other disease
  • Patients who have any known allergies
  • Non willing patients
  • Lactating women
  • Pregnant women
  • Smokers

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Conventional group
Control group
实验性的:Intervention group
Targeted group with intervention
Grape-C supplement purchased from Nutrifactor brand.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Bilirubin levels
大体时间:4 weeks
In this study results showed the significant decrease in bilirubin levels in interventional group as compared to the conventional group
4 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Dr Habib-ur-Rehman Rehman, PhD Food and Nutrition、University of Lahore

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

  • DOI: 10.4103/1319-3767.65197

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月3日

初级完成 (实际的)

2023年3月17日

研究完成 (实际的)

2023年4月4日

研究注册日期

首次提交

2026年5月4日

首先提交符合 QC 标准的

2026年5月4日

首次发布 (实际的)

2026年5月8日

研究记录更新

最后更新发布 (实际的)

2026年5月12日

上次提交的符合 QC 标准的更新

2026年5月7日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • AZ786
  • University of Lahore (其他标识符:Self)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅